Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225433 · ClinicalTrials.gov registry record · Phase 4
Luteal Phase FSH in the IVF Poor Responder
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00225433: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00225433 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225433, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retrieved, a women undergoes ovarian stimulation with recombinant follicle stimulating hormone (FSH). Typically 6-20 oocytes are retrieved, but in some cases there is a limited response to the stimulation, producing a limited number of oocytes. This is called poor ovarian response. This study is designed to objectively compare two treatment regimens currently advocated in clinical practice, but never compared directly. The purpose is to assess ovarian response to starting treatment at the end of the preceding cycle may increase the number of developing oocytes.
Interventions
- DRUG ganirelix acetate
- DRUG follitropin beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225433
The ClinicalTrials.gov registry entry for NCT00225433 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ganirelix acetate is the first listed.
NCT00225433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225433 about?
NCT00225433 is a clinical study titled "Luteal Phase FSH in the IVF Poor Responder". In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retriev...
What is the current status of trial NCT00225433?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2005-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00225433?
The interventions under investigation include: ganirelix acetate (DRUG), follitropin beta (DRUG).
Who is sponsoring clinical trial NCT00225433?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.